LITMYS: TURNING CLINICAL PROMISE INTO COMMERCIAL SUCCESS
"Litmys helps life science product decisionmakers move beyond quick KOL calls. They use smarter, structured approaches to evaluate market positioning and maximize the value of every development dollar."
– CEO and Portfolio Manager, Biotech Venture Company
Litmys is a commercial strategy consulting firm that helps life science innovators ensure that products gaining regulatory approval also achieve market adoption. Working with pharmaceutical, biotech, and medical device companies and their investors, Litmys brings commercial clarity before significant and irrevocable clinical trial investments are made, i.e. before Phase 3.
Litmys future-proofs your new products by aligning clinical and commercial plans with payer, provider and patient needs. Our proprietary methods reveal whether a product will truly stand out in the post-launch real world, helping CEOs prioritize assets, secure funding, and build confidence before costly clinical commitments are made.
The Challenge
~50%
of new drugs fail to meet their post-launch forecasts.
<6%
R&D productivity remains under 6%.
80%
of physicians are employees under pressure to maximize patient volume and are resistant to changing prescribing behavior.
Payers are tightening reimbursement and raising evidence standards.